Search research articles
Contact Us
Filters
Showing results (81-90 of 278) with videos related to
Page
of 28
Sort By:
Diagnostic Microbiology and Infectious Disease
|
March 24, 2018
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014
M A Pfaller, H S Sader, R K Flamm, et al.
International Journal of Antimicrobial Agents
|
March 7, 2018
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
Michael A Pfaller, Michael D Huband, Rodrigo E Mendes, et al.
Journal of Global Antimicrobial Resistance
|
July 24, 2017
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015)
Michael A Pfaller, Rodrigo E Mendes, Helio S Sader, et al.
Open Forum Infectious Diseases
|
March 22, 2019
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997-2016
Michael A Pfaller, Martin Cormican, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy
|
February 11, 2015
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide
Ronald N Jones, John D Turnidge, Greg Moeck, et al.
The Journal of Antimicrobial Chemotherapy
|
July 27, 2022
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19)
Helio S Sader, Rodrigo E Mendes, Leonard R Duncan, et al.
Open Forum Infectious Diseases
|
February 27, 2023
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021)
Helio S Sader, Rodrigo E Mendes, Cecilia G Carvalhaes, et al.
Antimicrobial Agents and Chemotherapy
|
March 6, 2023
Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020)
S J Ryan Arends, Deborah Butler, Nicole Scangarella-Oman, et al.
International Journal of Antimicrobial Agents
|
May 9, 2026
Multidrug-Resistant Enterobacterales in United States Hospitals: Frequency and Susceptibility to Newer β-Lactamase Inhibitor Combinations (2020-2024)
Helio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.
Antibiotics (Basel, Switzerland)
|
April 27, 2026
Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> from Elderly Patients in Intensive Care Units of United States Medical Centers (2021-2025)
Helio S Sader, Rodrigo E Mendes, Timothy B Doyle, et al.
Page
of 28
Search research articles
Search
Showing results (81-90 of 278) with videos related to
Sort By:
Page
of 28
Diagnostic Microbiology and Infectious Disease
|
March 24, 2018
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014
M A Pfaller, H S Sader, R K Flamm, et al.
International Journal of Antimicrobial Agents
|
March 7, 2018
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
Michael A Pfaller, Michael D Huband, Rodrigo E Mendes, et al.
Journal of Global Antimicrobial Resistance
|
July 24, 2017
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015)
Michael A Pfaller, Rodrigo E Mendes, Helio S Sader, et al.
Open Forum Infectious Diseases
|
March 22, 2019
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997-2016
Michael A Pfaller, Martin Cormican, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy
|
February 11, 2015
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide
Ronald N Jones, John D Turnidge, Greg Moeck, et al.
The Journal of Antimicrobial Chemotherapy
|
July 27, 2022
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19)
Helio S Sader, Rodrigo E Mendes, Leonard R Duncan, et al.
Open Forum Infectious Diseases
|
February 27, 2023
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021)
Helio S Sader, Rodrigo E Mendes, Cecilia G Carvalhaes, et al.
Antimicrobial Agents and Chemotherapy
|
March 6, 2023
Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020)
S J Ryan Arends, Deborah Butler, Nicole Scangarella-Oman, et al.
International Journal of Antimicrobial Agents
|
May 9, 2026
Multidrug-Resistant Enterobacterales in United States Hospitals: Frequency and Susceptibility to Newer β-Lactamase Inhibitor Combinations (2020-2024)
Helio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.
Antibiotics (Basel, Switzerland)
|
April 27, 2026
Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> from Elderly Patients in Intensive Care Units of United States Medical Centers (2021-2025)
Helio S Sader, Rodrigo E Mendes, Timothy B Doyle, et al.
Page
of 28